Generic Medicine Info
Indications and Dosage
Acute migraine attacks
Adult: Initially, 40 mg, may repeat after at least 2 hr if symptoms recur w/in 24 hr (2nd dose should not be taken for same attack). Max: 80 mg daily.
Renal Impairment
Mild to moderate: Initially, 20 mg. Max: 40 mg daily. Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Hypersensitivity to eletriptan. Known or suspected ischaemic heart disease (e.g. angina pectoris, MI, silent ischaemia), coronary artery vasospasm (e.g. Prinzmetal variant angina), severe or uncontrolled HTN, Wolff-Parkinson-White syndrome or arrhythmias, heart failure, previous CVA or TIA, peripheral vascular disease, ischaemic bowel disease, basilar or hemiplegic migraine. Severe hepatic and renal impairment. Concomitant admin w/ 5-HT1 receptor agonists or ergot alkaloids.
Special Precautions
Patient at risk of coronary artery disease (e.g. HTN, DM, hypercholesterolaemia, smoker or user of nicotine therapy, post-menopausal women, men >40 yr, strong family history of coronary artery disease, obesity). Mild to moderate renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Medication overuse headache (MOH). Rarely, elevation in BP (e.g. hypertensive crisis).
Nervous: Headache, seizure, asthenia, paraesthesia, dizziness, somnolence.
CV: Chest pain, palpitations, tachycardia, flushing.
GI: Dry mouth, nausea, dyspepsia, dysphagia, abdominal pain, vomiting.
Others: Weakness.
Potentially Fatal: Cardiac rhythm disturbances (e.g. ventricular tachycardia or fibrillation), MI, coronary artery vasospasm, cerebral or subarachnoid haemorrhage, stroke, peripheral vascular ischaemia, GI vascular ischaemia, infarction, Raynaud’s syndrome, anaphylactic reactions (e.g. angioedema).
Patient Counseling Information
This drug may cause dizziness, somnolence, or weakness, if affected, do not drive or operate machinery.
Monitoring Parameters
Determine a clear diagnosis of migraine before treatment. Monitor CV status prior initiation of treatment and periodically thereafter; hepatic and renal function. Perform periodic CV evaluation for patients w/ risk factors for coronary artery disease who are receiving intermittent long-term therapy.
Symptoms: HTN and other CV symptoms. Management: Supportive treatment.
Drug Interactions
Increased peak plasma concentration w/ potent CYP3A4 enzyme inhibitors (e.g. ketoconazole, clarithromycin, ritonavir). Potential risk of serotonin syndrome w/ SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).
Potentially Fatal: May cause additive vasospastic effect when used concomitantly w/ ergot alkaloids (e.g. ergotamine, dihydroergotmaine, methysergide) or other 5-HT1 receptor agonists.
Food Interaction
Increased bioavailability w/ high-fat meal.
Description: Eletriptan is a selective agonist of serotonin (5-HT1B/1D/1F) receptors. It causes constriction of intracranial blood vessels and reduction of sterile inflammation associated w/ antidronic neuronal transmission, thereby relieving migraine.
Absorption: Well absorbed. Bioavailability: Approx 50%. Time to peak plasma concentration: 1.5-2 hr.
Distribution: Enters breast milk (small amount). Volume of distribution: 138 L. Plasma protein binding: Approx 85%.
Metabolism: Metabolised in the liver by CYP3A4 enzyme to the active, N-demethylated metabolite.
Excretion: Elimination half-life: Approx 4 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Eletriptan, CID=77993, https://pubchem.ncbi.nlm.nih.gov/compound/Eletriptan (accessed on Jan. 22, 2020)

Store between 20-25°C.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CC06 - eletriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Anon. Eletriptan. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/03/2017.

Buckingham R (ed). Eletriptan Hydrobromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017.

Joint Formulary Committee. Eletriptan. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Eletriptan Hydrobromide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/03/2017.

Relpax Tablet, Film Coated (Roerig). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/03/2017.

Disclaimer: This information is independently developed by MIMS based on Eletriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in